DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Eltrombopag

Eltrombopag

  • Quarterly Review

    Quarterly Review

  • Managing Adverse Effects and Complications in Completing Treatment for Hepatitis C Virus Infection

    Managing Adverse Effects and Complications in Completing Treatment for Hepatitis C Virus Infection

  • Investor Presentation

    Investor Presentation

  • Summary of Appeals & Independent Review Organization

    Summary of Appeals & Independent Review Organization

  • And Intermediate-1-Risk MDS

    And Intermediate-1-Risk MDS

  • Samaritan Fund

    Samaritan Fund

  • Eltrombopag, a Thrombopoietin Receptor Agonist, Enhances Human

    Eltrombopag, a Thrombopoietin Receptor Agonist, Enhances Human

  • Romiplostim (Nplate), Eltrombopag (Promacta)

    Romiplostim (Nplate), Eltrombopag (Promacta)

  • DTF Prior Authorization Drug List

    DTF Prior Authorization Drug List

  • Medicare Plus Blue PPO Assure & PDP Option B. Prior Authorization/Step Therapy

    Medicare Plus Blue PPO Assure & PDP Option B. Prior Authorization/Step Therapy

  • Prescribing Information

    Prescribing Information

  • Iron and Leukemia: New Insights for Future Treatments Fang Wang1, Huanhuan Lv1,2,3, Bin Zhao1, Liangfu Zhou1, Shenghang Wang1, Jie Luo1, Junyu Liu1 and Peng Shang2,3*

    Iron and Leukemia: New Insights for Future Treatments Fang Wang1, Huanhuan Lv1,2,3, Bin Zhao1, Liangfu Zhou1, Shenghang Wang1, Jie Luo1, Junyu Liu1 and Peng Shang2,3*

  • Thrombopoietin Receptor Agonist Eltrombopag Prevents Insulin

    Thrombopoietin Receptor Agonist Eltrombopag Prevents Insulin

  • Eltrombopag) Tablets, for Oral Use Most Patients

    Eltrombopag) Tablets, for Oral Use Most Patients

  • Eltrombopag Versus Romiplostim in Treatment of Children With

    Eltrombopag Versus Romiplostim in Treatment of Children With

  • Stable Liver Function During Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease

    Stable Liver Function During Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease

  • PROMACTA (Eltrombopag) Tablets • PROMACTA May Cause Hepatotoxicity

    PROMACTA (Eltrombopag) Tablets • PROMACTA May Cause Hepatotoxicity

  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION

    COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION

Top View
  • PDL DRUG REVIEW Proprietary Name: Zeposia® Common Name: Ozanimod PDL Category: Multiple Sclerosis Agents
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
  • NEW 2018 Specialty Drugs
  • The Effect of Eltrombopag in Managing Thrombocytopenia Associated With
  • Lumicera Specialty Drug List
  • Brand Generic Guide
  • Proposed Formulary Changes Effective 4-1-2019 (Unless Otherwise Noted)
  • 07 Poster Viewing I 65..65
  • The Role of Eltrombopag and Romiplostim As The
  • Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia
  • PROMACTA (Eltrombopag) RATIONALE for INCLUSION IN
  • Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions David J
  • Eltrombopag (Revolade) for Severe Aplastic Anaemia – First Line
  • Drug Safety Update
  • Pharmacy Specialty Drug Policies
  • The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation
  • JAKAFI® Or PROMACTA®
  • Successful Treatment of Secondary Poor Graft Function Post Allogeneic


© 2024 Docslib.org    Feedback